Join the club for FREE to access the whole archive and other member benefits.

Ambrosia ceases young blood plasma treatment


Key points from article :

FDA says there is no proven clinical benefit of infusion of plasma from young donor.

Ambrosia has confirmed that it has ceased patient treatments.

Company had referred to its intravenous infusions of plasma as a medical treatment.

Ambrosia's trial was not performed under the Investigational New Drug (IND) program.

FDA concerned patients may be discouraged from seeking safe and effective treatments for serious illnesses.

Only 2 months after starting. Calling it a medical treatment may be contravened FDA guidance.

Mentioned in this article:

Tap on icon for description, click on resource name for more details.


Offers young blood plasma transfers after running a trial in 2016-18


Ensuring safety of drugs, medical supplies and food which is used daily.


American physician and investor.

Ambrosia ceases young blood plasma treatment